ctDNA predicts resistance to AR-targeted therapy

Date Posted: 
2018-01-26

Drs. Wyatt, Chi and their teams have a new Cancer Discovery publication, "Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer,"  in which they identify novel genomic biomarkers that could ultimately help decide whether patients with advanced prostate cancer should receive abiraterone or enzalutamide. These biomarkers are available via a non-invasive technique, and therefore this analysis is highly suitable for integration into general clinical practice.
 
The standard of care therapies for metastatic castration-resistant prostate cancer, abiraterone and enzalutamide, are not effective in 10-30% of patients. We currently are unable to recognize this subset of patients up-front, which means they are treated with a drug that will not work and which gives them unnecessary treatment side-effects.

Our unique research team combines cancer bioinformatics expertise (Wyatt) with clinical oncology (Chi) to develop genomic-based strategies that better recognize patients with poor prognoses. Our prior work has shown that changes detected in ctDNA accurately reflect cancer itself and can therefore show the DNA changes occurring in a patient’s prostate cancer before, during, and after treatment.

In this paper we looked at changes occurring in the ctDNA of 202 Canadian men with prostate cancer enrolled on a phase II clinical trial comparing treatment with abiraterone to enzalutamide. We determined which changes can predict a patient’s subsequent response to treatment. In particular, alterations in DNA repair genes and the gene TP53 were strongly linked to poor outcomes with both therapies – and were independent of standard prognostic biomarkers (i.e. they provide prognostic information beyond what is currently available from clinical metrics). We also identified novel AR gene alterations (the AR is the central target of both therapies) in several patients who derived no benefit from therapy.

This work was supported by grants from the Canadian Cancer Society, Prostate Cancer Canada/Movember Canada, the Emil Aaltonen Foundation, the Prostate Cancer Foundation, and The Terry Fox Research Institute, as well as clinical trials funding from Janssen and Astellas.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Rock4Prostate

Rock4Prostate fundraiser - Friday Nov 8, 2019

The 2nd annual Rock4Prostate event takes place Friday Nov 8 at the Backstage Lounge Pub on Granville Island.  Tickets available at Eventbrite and at the door ($20 or $10 for students 19+), with proceeds going to Prostate Cancer Canada.  Please visit the Facebook event page for more details

VPC Movember 2013 team

Movember fundraiser: Nov. 1 - 30, 2019

Movember is an international charity raising funds for men's health initiatives. Movember Canada focuses on prostate cancer, testicular cancer, mental health and suicide prevention. Please visit moteam.co/the-vancouver-prostate-centre to join or donate to our Centre's Movember fundraising team.

Employment

Work at the Vancouver Prostate Centre

Monday, September 16, 2019

Drs Cox, Gleave and Goldenberg awarded Prostate Cancer Canada and Movember 2019 Discovery Grants

Drs Cox, Gleave and Goldenberg
Thursday, September 12, 2019

Drs. Wyatt and Sorensen receive 2019 UBC Faculty of Medicine Awards for Distinguished Achievement

Drs Wyatt and Sorensen
Tuesday, September 10, 2019

Drs. Sorensen, Ester and Huntsman elected to Royal Society of Canada

Drs Sorensen, Ester, Huntsman